Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection (CurHP)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Gingold Belfer Rachel, Rabin Medical Center.
Recruitment status was:  Not yet recruiting
Information provided by (Responsible Party):
Gingold Belfer Rachel, Rabin Medical Center Identifier:
First received: December 17, 2013
Last updated: December 13, 2014
Last verified: December 2014

Background and Aims

  • H.pylori is a common human pathogen by which almost 50% of the world population is infected. According to the accepted guidelines, once H.pylori infection has been diagnosed,first line therapy with three drugs should be given. The triple treatment includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is only 70-80%.
  • Curcumin has many beneficial merits and it was also been demonstrated to be efficient in inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether addition of Curcumin to the standard triple therapy will increase the eradication rate of H.pylori infection.


  • 150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology department and will be positive for H.pylori according to urease test and then by gastric biopsy, will be included. The patients will be randomized to two different treatments, according to binomial distribution. 75 patients will be treated with the standard triple therapy for 10 days and the other 75, will be treated for 10 days, with triple therapy combined with Curcumin that will be given three times a day.
  • During the treatment the patients will complete an adverse effect's questionnaires. 6 weeks after the completion of the treatment the patients will undergo urea breath test to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds or proton-pump-inhibitor until the second urea-breath-test.
  • We will compare the eradication rate and the adverse effects between the two groups by using SPSS

Condition Intervention
Positivity for Helicobacter Pylori
Dietary Supplement: Curcumin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection

Resource links provided by NLM:

Further study details as provided by Gingold Belfer Rachel, Rabin Medical Center:

Primary Outcome Measures:
  • Urea breath test [ Time Frame: 6 weeks after the completion of the treatment ]

Estimated Enrollment: 150
Study Start Date: January 2014
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Triple therapy, helicobacter pylori
Experimental: triple therapy+curcumin helicobacter pylori
Curcumin will be added to the regular triple therapy
Dietary Supplement: Curcumin


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • positivity for Helicobacter pylori by urease test and gastric biopsy

Exclusion Criteria:

  • prior treatment for H. pylori
  • allergy to penicillin
  • gastric outlet obstruction
  • pregnancy or breast feeding
  • inability to understand the informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02018328

Contact: Rachel Gingold belfer, MD

Rabin Medical Center Not yet recruiting
Petah Tikva, Israel, 49100
Contact: Rachel Gingold Belfer, MD    974-54-2405895   
Principal Investigator: Rachel Gingold Belfer, MD         
Rabin Medical Center Not yet recruiting
Petah tikva, Israel
Contact: Rachel Gingold Belfer, MD    974-54-2405895   
Principal Investigator: Rachel Ginold Belfer, MD         
Sponsors and Collaborators
Gingold Belfer Rachel
  More Information

Malfertheiner P, Megraud F. Management of helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut.61 (5):646-64.2012 Hatcher H , Planalp R . Curcumin: from ancient medicine to cuurent clinical trials. Cell Mol Life Sci. 65(11):1631-52. 2008. Forty-Ludwig A, Neumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori - infected epithelial cells. Biochem Biophys Res Commun. 316(4): 1065-72. 2004

Responsible Party: Gingold Belfer Rachel, MD, Rabin Medical Center Identifier: NCT02018328     History of Changes
Other Study ID Numbers: rmc137511
Study First Received: December 17, 2013
Last Updated: December 13, 2014

Additional relevant MeSH terms:
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017